Rapcabtagene Autoleucel (YTB323) in Patients (Pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Phase II Trial Clinical Update

Oral Presentation
© 2024 American Society of Hematology. All rights reserved.
Meeting: 2024 ASH® Annual Meeting
Indication: Diffuse Large B-Cell Lymphoma (DLBCL)
Presenter: Peter A. Riedell, MD
Affiliation: David and Etta Jonas Center for Cellular Therapy, University of Chicago, Chicago, IL
Presentation Date: December 7, 2024
Abstract Number: 67
Session: Session: 628. Aggressive Lymphomas: Cellular Therapies: Novel Strategies for Cell Therapies in Aggressive Lymphomas

To access this content please accept the following declarations.

This content was selected by and is provided to you upon your unsolicited request courtesy of Novartis with permission of ASH®.